More than half of all patients with major depressive disorder (MDD) experience a relapse within 2 years after recovery. It is unclear how relapse affects brain morphologic features during the course of MDD.
L ess than half of all patients with major depressive disorder (MDD) remain free of symptoms for 2 years after recovery. 1 Rates of relapse increase markedly with subsequent episodes, which leads to a continuous high risk of chronicity and negative psychosocial consequences among these patients. 2, 3 Structural neuroimaging techniques may provide insights into the underlying neural mechanisms of relapse. In the long term, understanding the neuronal correlates could support prognosis of relapse and thus improve maintenance treatment in patients with recurrent MDD. Major depressive disorder is associated with morphologic changes in specific brain areas, most prominently the hippocampus, 4 -7 insula, [8] [9] [10] [11] and the prefrontal and orbitofrontal cortex (OFC). 6, [11] [12] [13] [14] Cross-sectional studies have repeatedly reported that these brain alterations are strongly influenced by the course of illness (eg, number of recurrent episodes, 8,15 duration of untreated depression, 16 and early age of depression onset 17 ). These findings could indicate that depression causes damage to the brain that evolves over time and is most obvious in individuals with progressive and recurrent MDD. 18 However, this conclusion must be treated with caution, since only correlative statements can be drawn from cross-sectional studies. Despite intense research on the clinical correlates of morphologic brain alterations in patients with MDD, longitudinal studies in well-characterized samples are needed to gauge neurobiological changes due to relapse. So far, most longitudinal studies have investigated morphologic changes in dependence of remission status at follow-up assessment. Several studies found that patients whose MDD was not in remission at follow-up showed significantly more volume decline compared with patients whose MDD was in remission (eg, in the hippocampus, anterior cingulate cortex [ACC] , and dorsolateral prefrontal cortex [DLPFC] ). [19] [20] [21] [22] Other studies showed normalized volume and thickness in the hippocampus, rostral middle frontal gyrus (MFG), and OFC in patients who achieved remission. 23, 24 However, to evaluate the association between brain alterations and relapse, it is crucial to consider the course of illness between scans, which has been neglected by most studies. To our knowledge, only 1 study reported an association of gray matter reductions and the number of relapses in a 7-year follow-up, 25 but control for confounding variables (eg, medication) was lacking in the statistical analyses. Furthermore, most results are limited to geriatric populations, and younger samples are required for generalizability of these findings. [21] [22] [23] [26] [27] [28] [29] [30] Most previous studies used restricted regionof-interest analyses rather than whole-brain approaches, which a priori limited the outcomes to a subset of regions of the brain.
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To enhance our understanding of structural brain alterations in patients with recurrent MDD, the aim of our study was to investigate morphologic changes in patients as a function of relapse during the follow-up interval using both wholebrain voxel-based morphometry (VBM) and region-ofinterest analysis by FreeSurfer (https://surfer.nmr.mgh.harvard .edu). We hypothesized that patients with at least 1 relapse between scans show more pronounced reductions in gray matter than patients who achieved stable remission during the follow-up interval. Severity of depression at follow-up was controlled for to investigate whether potential brain changes merely reflect state-dependent differences owing to remission status, or rather result from relapse. Our longitudinal design also implemented correlational control for confounding effects of psychiatric medication.
Methods

Participants and Procedure
The study comprised 64 patients with MDD and 59 matched healthy controls who were recruited from the University of Münster Department of Psychiatry from . Following data quality checks (eAppendix 1 in the Supplement), the final sample consisted of 60 patients and 54 healthy controls. Participants received financial compensation. The study was approved by the institutional review board of the medical faculty of the University of Münster and all participants provided written informed consent.
Participants received diagnoses according to the Structured Clinical Interview for DSM-IV 32 at both time points. At baseline, medical records were consulted to validate the diagnosis and duration of the index episode of MDD. We used structured interviews to retrospectively assess the type and dose of psychopharmacologic treatment at baseline and follow-up (Table 1) , as well as the days between scans without medication. We used this information to compute a composite medication index (eAppendix 1 in the Supplement). The Hamilton Depression Rating Scale 33 was applied to capture the severity of symptoms at both time points. Furthermore, we assessed familial risk for MDD and childhood maltreatment with the Childhood Trauma Questionnaire 34 as known risk factors for both MDD and morphologic brain changes.
35-37
All patients were experiencing a moderate or severe depressive episode at baseline, resulting in inpatient treatment. Depending on the course of illness between scans, we divided patients into 2 groups: patients with no subsequent episodes (no relapse; n = 23), and patients who experienced at least 1 additional episode (relapse; n = 37). We applied
Key Points
Question Is relapse in major depressive disorder associated with morphologic brain changes?
Findings In this longitudinal, case-control, magnetic resonance imaging study, patients with major depressive disorder showed different trajectories of cortical gray matter changes depending on whether they experienced a relapse during the follow-up interval. These changes were not significantly associated with psychiatric medication or with severity of depression at follow-up.
Meaning Relapse in major depressive disorder is associated with morphologic changes in brain regions that are crucial for regulation of emotions and cognitive control.
DSM-IV criteria using the Structured Clinical Interview for DSM-IV for assessing relapse during the follow-up interval and determining full remission (absence of symptoms for at least 2 months), which was required before diagnosing a new episode. Given the limited number of possible episodes in a 2-year interval, and the insufficient number of patients with more than 1 episode, we refrained from assessing the parametric effects of the number of relapses.
At baseline, patient groups did not differ significantly in clinical and sociodemographic variables. However, patients with relapse had significantly higher Hamilton Depression Rating Scale scores at follow-up than did patients without relapse. All 3 groups did not differ significantly in age, sex, educational level, and time between scans ( Table 2) . For further information on sample matching, see eAppendix 1 in the Supplement. 
Magnetic Resonance Imaging Procedure
The T1 images were acquired using a 3-T scanner. For a detailed description of data acquisition, see eAppendix 1 in the Supplement.
Voxel-Based Morphometry
Gray matter information was analyzed using the default longitudinal preprocessing pipeline of the Computational Anatomy Toolbox (http://www.neuro.uni-jena.de/cat, v933). Processing steps included intraparticipant realignment of baseline and follow-up images to a mean image for each participant, to evaluate within-participant dependency of images over time.
Following bias correction, spatial normalization parameters were estimated based on the mean image using high-dimensional Diffeomorphic Anatomical Registration Through Exponentiated Lie Algebra (DARTEL) normalization, and applied to baseline and follow-up images. Images were segmented into gray matter, white matter, and cerebrospinal fluid. Gray matter images were smoothed with an 8-mm full-width at half maximum Gaussian kernel. For details on data quality checks, see eAppendix 1 in the Supplement.
Surface-Based Morphometry
Based on recent studies reporting cortical alterations in patients with MDD, 11, 24 we selected the insula, medial OFC, rostral ACC, and rostral middle frontal gyrus as regions of interest for additional analysis of cortical thickness. For both VBM and SBM analyses, a 3 × 2 analysis of covariance (ANCOVA) with group (no relapse, relapse, and healthy controls) as between-participant factor and time (baseline and follow-up) as within-participant factor was computed. Age and total intracranial volume (for VBM only) were included as covariates. We performed F tests for the main effects of group and the group-by-time interaction. Bonferroni-corrected pairwise comparisons were calculated to further investigate significant effects. For VBM volumes, pairwise comparisons were computed on extracted contrast values of the significant clusters in SPSS.
Anatomical labeling of significant VBM clusters was performed by the automated anatomical labeling atlas 41 implemented in the Wake Forest University pickatlas. 42 We used a rigorous statistical threshold of P < .05 (2-sided), familywise error corrected on the voxel level. 43 Exploratory results are also reported at a statistical threshold of P < .001, uncorrected, and a cluster threshold of k = 300 voxels. For the patient subsamples, VBM gray matter volume differences were computed by subtracting contrast values extracted at baseline from those at follow-up. We performed correlation analyses to investigate potentially confounding effects of medication and symptom severity at follow-up on gray matter volumes and on gray matter volume differences.
Results
The study included 60 participants with MDD: 23 without relapse (13 women and 10 men; mean [SD] 
Whole-Brain Analysis (VBM)
The ANCOVA showed a significant interaction of group by time when controlling for age and total intracranial volume, which comprised clusters in the right insula and the right DLPFC (Table 3 and Figure) . Exploratory analyses revealed an additional interaction in the ACC and in the middle and superior temporal gyrus (eTable 1 and eFigure in the Supplement).
In the insula, pairwise comparisons on the extracted cluster values revealed a significant increase in volume between baseline and follow-up in healthy controls (difference, 0.060; 95% CI, 0.034-0.085; P < .001) and a significant decrease in volume between baseline and follow-up in patients with relapse (difference, −0.032; 95% CI, −0.063 to −0.002; P = .04), whereas there was no significant change in patients without relapse (difference, 0.027; 95% CI, −0.012 to 0.066; P =.17) ( Table 4 and Figure) . In the DLPFC, there was a significant decrease in volume between baseline and follow-up in patients with relapse (difference, −0.079; 95% CI, −0.113 to −0.045; P < .001) but no significant change in patients without relapse (difference, 0.023; 95% CI, −0.020 to 0.066; P = .30) or healthy controls (difference, 0.010; 95% CI, −0.018 to 0.038; P = .48) ( Table 4 and Figure) . The pattern of interaction effects remained the same if the ANCOVA was repeated considering only patient subgroups (eAppendix 2 in the Supplement). For the patient subgroups, neither symptom severity nor medication load index were significantly correlated with gray matter volume differences or gray matter volumes at follow-up (eTable 2 in the Supplement). At baseline, patients with relapse between scans had significantly higher gray matter volume compared with patients without relapse (only in the DLPFC) and healthy controls (both in the DLPFC and insula). Details on the main effect of group and group differences at baseline and follow-up can be found in eAppendix 2 in the Supplement.
Region-of-Interest Analysis (SBM)
The ANCOVA showed a significant group-by-time interaction for cortical thickness of the left medial OFC and left rostral ACC (eTable 3 in the Supplement). For both regions, patients without relapse had a significant increase of cortical thickness (ACC: difference, 0.073 mm; 95% CI, 0.023-0.123 mm; P = .005; OFC: difference, 0.089 mm; 95% CI, 0.032-0.147 mm; P = .003), as did healthy controls (ACC: difference, 0.087 mm; 95% CI, 0.056-0.118 mm; P < .001; OFC: difference, 0.048 mm; 95% CI, 0.013-0.083 mm; P = .007), whereas there was no significant change in patients with relapse (ACC: difference, 0.003 mm; 95% CI, -0.035 to 0.041 mm; P = .86; OFC: difference, -0.006 mm; 95% CI, -0.047 to 0.036 mm; P = .79). Although the group-by-time interaction failed to reach significance for the right insula, pairwise comparisons revealed the same pattern of change. In the right rostral middle frontal gyrus, we observed a decrease of cortical thickness in patients with relapse whereas patients without relapse and controls did not show a significant change. Results from pairwise comparisons of longitudinal effects within groups are presented in Table 4 .
Discussion
Distinct associations of relapse in MDD with brain morphologic features were revealed using a longitudinal magnetic resonance imaging design and a combined VBM and SBM approach. Patients who experienced at least 1 relapse between scans showed a decline of insular volume and DLPFC volume and thickness from baseline to follow-up. In patients without relapse, gray matter volume in these regions was stable, whereas cortical thickness increased in the left medial OFC, left rostral ACC, and right insula. Volume changes from baseline to follow-up were not associated with psychiatric medication or with severity of depression at follow-up. Together, these results highlight the effects of relapse on morphologic brain alterations in patients with MDD.
The observed neuroplastic changes in the insula, ACC, and prefrontal cortex are in line with neurobiological models of MDD that assume a dysfunction of the frontolimbic brain circuitry. 44 Cross-sectional studies often report changes of insular volume and thickness in patients with MDD. remission. 24 On the functional level, magnetic resonance imaging studies on the prefrontal cortex might point at a deficit in cognitive control and emotion regulation.
55-57
The rostral ACC has been reported to be decreased in individuals with MDD, especially with multiple depressive episodes. 11, 12 Our results are supported by findings on less decrease of the left ACC in patients without remission compared with those with remission. 19 Changes in ACC volume have been shown to be correlated with faster rates of symptom improvement, 58 which fits with our observation that an increase in ACC thickness might be associated with a beneficial course of illness. Taken together, our present findings on insular, ACC, and prefrontal atrophy in patients with recurrent MDD shed light on the development of a bottom-up processing bias of emotional stimuli (eg, in limbic brain areas) and a disruption of top-down executive functions (eg, in the DLPFC or OFC and ACC). For both the DLPFC and the insula, we found only rightlateralized effects. These findings would be consistent with theories on a right-hemispheric specialization to aversive emotion processing and regulation. 59 However, complementary analyses with FreeSurfer showed left-lateralized effects in the medial OFC and rostral ACC. Thus, laterality effects could not be supported, possibly owing to differences in preprocessing and segmentation. Future studies need to directly investigate hemispheric lateralization. Previous longitudinal studies on morphologic changes in MDD provided no information on the course of illness between scans [19] [20] [21] [22] but mainly reported associations with remission status, including current depressive symptoms at followup. Therefore, these studies could not disentangle the effects of remission status from differing courses of depression. The morphologic alterations observed when contrasting patients with and patients without remission might thus be better explained by differences in depressive episodes between scans and less by state differences. Regional morphologic changes of the cortex as a putative cumulative effect of illness duration and relapse are supported by studies that elucidate progressive neural changes in association with recurrent episodes. [60] [61] [62] [63] We can only partly replicate previous findings on a gray matter volume increase in patients with remission 23,24 because there was only a tendency for an increase of cortical thickness in patients without relapse. Future studies should clarify whether there is a normalization of volume in patients without relapse, or whether an increase could be better explained by confounding variables exerting neuroprotective effects (eg, medication or psychotherapy). In our study, we observed larger baseline DLPFC volumes in patients with relapse than in patients without relapse, although patient groups did not differ in important confounding variables at baseline (eg, medication, depression severity, childhood maltreatment, and familial risk). Volume differences in the DLPFC could be explained by other variables that have not been assessed in this study. For example, environmental factors other than childhood maltreatment, such as urbanicity, could be associated with reduced volume and cortical thickness in the DLPFC.
64,65 Furthermore, unknown genetic factors contributing to both susceptibility for relapse and brain structure could be responsible for this finding. Alternatively, a larger DLPFC volume could be a correlate of increased disease vulnerability or could reflect a compensatory mechanism in individuals who are prone to relapse. Furthermore, our study might be underpowered to detect reliable cross-sectional associations owing to the small sample size. However, longitudinal studies require far fewer participants than do cross-sectional studies to detect small morphologic changes in the brain. 66 We found an increase of insular volume and thickness in controls. Research on normal brain changes across the lifetime in control populations describes a trend of decrease in volume after the age of 30 years.
67-70 However, an age-related decrease in volume has been derived mostly from cross-sectional studies, which could be confounded by cohort effects (eg, secular changes in nutrition, medical care, or lifestyle). 71 Furthermore, high and constant reliability of neuroimaging measures was demonstrated, both in our study (eAppendix 1 in the Supplement) and in other samples. 72 Finally, findings were independent of the applied method, and there were no changes to the scanner setting that could have confounded our findings. Surface-based morphometry and VBM partly revealed different results for the direction of morphologic trajectories. Because VBM incorporates information from multiple morphologic characteristics, such as cortical thickness, folding, gyrification, and volume, this might explain the inconsistencies in the results. Previous studies that used a multimethods approach showed a regionally dependent contribution of different surface properties to the VBM signal. 73 Furthermore, comparability between methods is limited owing to differences in delineation of anatomical regions and use of different atlases for labeling. Despite these methodological differences, significant associations between VBM and SBM measures could be reported in previous studies, 74,75 which indicates concordance of methods.
Strengths and Limitations
Our study has several strengths and methodological weaknesses. To our knowledge, this is the first longitudinal study that directly addressed the association of relapse with morphologic brain alterations in middle-aged patients with MDD. Owing to adaptive neural processes in MDD, it seems of great importance to assess the course of depression for a given time interval, rather than the remission status at a single time point. Furthermore, we used a multimethodological approach with SBM and VBM. Both methods are optimized for longitudinal designs, instead of nonblinded manual segmentation. Manual methods are subject to errors in both accuracy and reproducibility (eg, through subjectivity in structure interpretation). 76 We implemented control for important confounding variables (eg, age, depressive episodes, medication, severity of depression, childhood maltreatment, and familial risk). However, there might be other confounding variables (eg, psychotherapy, social support, urbanicity, and duration of depressive episodes) that should be addressed by future studies. Finally, our study is limited by the retrospective assessment of the course of illness during the follow-up interval based on patients' selfdisclosure, because self-reported clinical measures often have low accuracy owing to recollection biases in MDD. 77 
Conclusions
Our study revealed distinct effects of relapse in patients with MDD using a longitudinal design and a multimethodological approach. Observed cortical changes from baseline to follow-up affected brain structures that are crucial for regulation of emotions and thus need to be prevented. Our results illustrate the negative association of relapse with morphologic brain alterations and might be a step to guide future prognosis and maintenance treatment in patients with recurrent MDD.
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Recruitment and exclusion criteria
Patients were recruited from the inpatient service of the Department of Psychiatry, University of Muenster. Healthy controls were recruited by public notices and newspaper announcements. Exclusion criteria included (1) any history of neurological abnormalities or head injury with loss of consciousness; (2) chronic medical diseases; (3) history of alcohol or substance dependence; (4) diagnosis of bipolar, psychotic and personality disorders for MDD patients and any life-time psychiatric disorder for healthy controls; (5) former electroconvulsive therapy (6) inadequate knowledge of the German language; (7) usual magnetic resonance imaging contraindications.
Computation of medication load index
Type and dose of psychopharmacological treatment were assessed in structured clinical interviews at baseline and at follow-up. Using this information and the percentage of days without medication during the follow-up interval, we computed the following composite medication index. First, to measure the total medication load at baseline and follow-up, a strategy described earlier was used. 1 Each psychotropic medication was coded as absent = 0, low = 1 (equal or lower average dose), or high = 2 (greater than average dose), relative to the midpoint of the daily dose range recommended by Physician's-DeskReference. 2 A composite measure of total medication load was calculated for each individual, reflecting dose and variety of different medications taken, by summing all individual medication. Next, the mean of the total medication scores was calculated at both time-points. Finally, this total medication load mean was multiplied with the percentage of days receiving medication during follow-up, to integrate days without the influence of psychopharmacological treatment.
Comparison of sociodemographic and clinical variables between groups
All sociodemographic and clinical variables were visually inspected for normality using QQ-plots. For all normally distributed variables, we performed an analysis of variance (for comparison of all three groups) or independent two-sample t-test (for comparison of patient subgroups) to investigate possible group differences. If normality was not met, we instead performed non-parametric Kruskall-Wallis (for comparison of all three groups) or Mann-Whitney tests (for comparison of patient subgroups). Due to the violation of normality for medication load index and symptom severity, we consequently reported nonparametric Spearman-Rho correlation coefficients instead of parametric Pearson coefficients.
MRI data acquisition
T1-weighted high-resolution anatomical images of the head were acquired (Gyroscan Intera 3T, Philips Medical Systems, the Netherlands) at two time points (baseline and two-year follow-up) using a three-dimensional fast gradient echo sequence (turbo field echo), repetition time = 7.4 ms, echo time = 3.4 ms, flip angle = 9°, two signal averages, inversion prepulse every 814.5 ms, acquired over a field of view of 256 mm (feet-head) x 204 mm (anterior-posterior) x 160 mm (right-left), frequency encoding in feet to head direction, phase encoding in anterior-posterior and right-left direction, reconstructed to voxels of 0.5 mm × 0.5 mm × 0.5 mm.
Data quality checks for VBM and SBM segmentation
Data quality of VBM gray matter segments was verified by implemented CAT12-functions using the covariance structure of each image with all other images. Nine subjects were excluded as outliers based on a criterion of more than two standard deviations around the mean.
For quality checks of FreeSurfer ROI segmentations, we visually inspected each hemisphere following standardized ENIGMA protocols (http://enigma.ini.usc.edu/protocols/imaging-protocols). Additionally, each statistical outlier (± 2.698 standard deviations around the mean) was inspected and, if poorly segmented, excluded from ROI-analysis. The final sample size per group for each ROI is shown in Table4.
Retest-reliability coefficients for each single subject were calculated by using the covariance structure of the gray matter segments of each individual baseline assessment with its corresponding follow-up image. This procedure was also used for quality assurance since outlier can be detected as well as the correct labelling of pre-post image pairs can be confirmed. This analysis yielded very high retest-reliabilities with a range from r tt = .86 to r tt = .95 in healthy controls (r mean = .92). Reliabilities based on the whole sample (patients and controls) ranged from r tt = .84 to r tt = .95 (r mean = .92). Importantly, we found no significant correlation between days since study onset and the individual reliability measures (r = .07, P = .45), indicating that test-retest correlations remained stable during the course of the study. Comparing patients measured early versus late relative to study onset, did not yield a significant group difference in reliabilities (median split on days since study onset was performed; t 112 = .55, P = .59). For the FreeSurfer measures of cortical thickness, no individual reliabilities can be determined but one coefficient for each included anatomical ROI. Comparably high retest-reliabilities with a range from r tt = .66 to r tt = .91 (r mean = .79) were found for cortical thickness of the regions-of-interest in healthy controls. Reliabilities based on the whole sample (patients and controls) ranged from r tt = .60 to r tt = .91 (r mean = .76).
Particularly the insula and the DLPFC showed excellent reliability coefficients (left insula: r tt = .88; right insula: r tt = .91; left rostral MFG: r tt = .76; right rostral MFG: r tt = .83), despite a time interval of two years. During the investigated two-year follow-up interval, age-related or environmental effects on gray matter volume are very likely to add biologically plausible variation to structural MRI measures. [3] [4] [5] [6] Yet, both VBM and SBM presented stable estimates, which must be considered as an indicator of high reliability of our key neuroimaging dependent variables.
eAppendix 2. Results
Group by time interaction within patients with MDD
To demonstrate that the significant group by time interaction in the 3x2 ANCOVA was not solely driven by volume changes healthy controls, we repeated the ANCOVA considering only patients with MDD. In this model, a significant group by time interaction for the insular cluster emerged (F 1,58 = 7.87, P = .007). Bonferroni corrected pairwise comparisons revealed that insular gray matter volume did not change significantly in patients without relapse (P = .11), whereas patients with a relapse show a significant decline of volume over time (P = .02). Thus, the interaction of group by time also emerges with only the MDD groups considered and is not solely driven by the increase in the control group. In the DLPFC, we also see a significant group by time interaction (F 1,58 = 10.99, P = .002). Again, patients without relapse show no significant change of volume (P = .35), whereas patients with a relapse do show a decline (P < .001).
Group differences of VBM volume at baseline and follow-up
A significant main effect of group on whole-brain level was found for the right DLPFC (x = 34, y = 36, z = 28, F 2,220 = 14.74, P FWE = .03). Pairwise comparisons revealed that, averaged across time-points, patients with relapse had a significantly lower DLPFC than patients without relapse (P = .003) and healthy controls (P < .001).
Pairwise comparisons between groups were performed to investigate cross-sectional effects in the insula and DLPFC, separately for both time-points. At baseline, patients with relapse between scans had significantly higher gray matter volume in the insular cortex than healthy controls (P < .001), but the two patient groups did not differ (P = .62). This effect was reversed at follow-up, where patients with relapse had significantly lower gray matter volume than healthy controls (P = .006). At follow-up, there was a nonsignificant trend between the patient groups, with slightly lower volumes in patients with relapse than in patients without relapse (P = .06). A comparable pattern of effects was also observed within the DLPFC. Patients with relapse had significantly higher gray matter volume than healthy controls (P = .02) and patients without relapse (P = .03) at baseline. In contrast, at follow-up, patients with relapse showed a significant decrease in gray matter volume compared to both patients without relapse (P = .01) and healthy controls (P = .002). Notes. OFC = orbitofrontal cortex; ACC = anterior cingulate cortex; MFG = middle frontal gyrus.
